Polymersome Antigen Adjuvant Segmentation for Immune Response
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for eliciting an immune response, particularly for membrane proteins and infectious diseases, face challenges such as low response levels, instability of delivery vehicles, and inefficiencies in antigen presentation, leading to high costs and safety concerns with existing vaccines.
Innovation Solution
Administering two separate populations of polymersomes, one associated with an antigen and the other with an adjuvant, where the antigen is encapsulated or conjugated to the surface of the first population of polymersomes, and the adjuvant is encapsulated or conjugated to the surface of the second population, with a mean diameter of 120 nm or more, to enhance immune response efficiency.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If membrane proteins are used as antigens, then the immune response level is low, but using larger amounts of membrane proteins increases cost and difficulty of production
Solution Approach 1:
The patent divides the antigen delivery system into two separate polymersome populations: one carrying the membrane protein antigen and another carrying the adjuvant. This segmentation allows each component to be optimized independently and delivered to different immune cell compartments, improving the efficiency of the immune response per unit of membrane protein used.
Solution Approach 2:
The patent introduces polymersomes as intermediary carriers that protect and deliver the membrane protein antigen to antigen-presenting cells. The polymersome structure facilitates proper folding and presentation of the membrane protein, enhancing its immunogenicity without requiring increased amounts of the difficult-to-produce membrane protein.
2Reliability
If adjuvants are used to boost immunogenicity of solubilized antigens, then immune response is improved, but the method is inefficient and provides limited advantage
Solution Approach 1:
The patent segments the antigen and adjuvant into separate polymersome populations rather than combining them in a single formulation. This allows the adjuvant to be delivered to and activate antigen-presenting cells before they encounter the antigen, creating a more efficient and pronounced immune response compared to conventional co-delivery methods.
3Ease of operation
If liposomes are used as delivery vehicles, then uptake by antigen-presenting cells is efficient, but stability in the presence of serum components is poor
Solution Approach 1:
The patent changes the material composition from natural lipids to synthetic polymers, fundamentally altering the stability parameters while maintaining the desired cellular uptake properties. The polymersome structure provides enhanced stability in serum environments while preserving efficient interaction with antigen-presenting cells.
4Stability of the object's composition
If PEGylation and crosslinking are used to stabilize liposomes, then stability issues are reduced, but the system remains less efficient in uptake and cross-presentation
Solution Approach 1:
The patent changes the fundamental material parameter from lipid-based to polymer-based structures, achieving stability without the need for PEGylation or crosslinking modifications. This material substitution inherently provides both stability and efficient cellular uptake properties that the modified liposome systems fail to achieve.
Data Source
AI summary
The present invention relates to a method of eliciting an immune response in a subject by administration of an antigen and an adjuvant, wherein the antigen is associated with a first population of polymersomes, and wherein the adjuvant is associated with a second population of polymersomes, and wherein the two populations of polymersomes are administered to the subject. The present invention also relates to compositions such as vaccines comprising the two polymersome populations of the present invention, methods of eliciting an immune response or methods for treatment, amelioration, prophylaxis or diagnostics of a cancer, autoimmune or infectious disease, comprising providing polymersomes of the present invention.